International Journal of Endocrinology and Metabolism

Published by: Neoscriber Demo Publisher

Review of Rationale, Design, and Initial Findings: Tehran Lipid and Glucose Study

Fereidoun Azizi 1 , * , Azita Zadeh-Vakili 2 and Miralireza Takyar 1
Authors Information
1 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Endocrinology and Metabolism: October 2018, 16 (4 (Suppl)); e84777
  • Published Online: October 22, 2018
  • Article Type: Review Article
  • Received: September 1, 2018
  • Revised: October 2, 2018
  • Accepted: October 6, 2018
  • DOI: 10.5812/ijem.84777

To Cite: Azizi F, Zadeh-Vakili A , Takyar M. Review of Rationale, Design, and Initial Findings: Tehran Lipid and Glucose Study, Int J Endocrinol Metab. 2018 ; 16(4 (Suppl)):e84777. doi: 10.5812/ijem.84777.

Abstract
Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Rationale for Design of Tehran Lipid and Glucose Study
3. Initial Findings of Tehran Lipid and Glucose Study
4. Discussion
References
  • 1. Azizi F, Mehran L. Experiences in the prevention, control and elimination of iodine deficiency disorders: A regional perspective. East Mediterr Health J. 2004;10(6):761-70. [PubMed: 16335762].
  • 2. Ordookhani A, Mirmiran P, Hajipour R, Hedayati M, Azizi F. Screening for congenital hypothyroidism in the Islamic Republic of Iran: Strategies, obstacles and future perspectives. East Mediterr Health J. 2002;8(4-5):480-9. [PubMed: 15603028].
  • 3. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5. doi: 10.1186/1745-6215-10-5. [PubMed: 19166627]. [PubMed Central: PMC2656492].
  • 4. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran Lipid and Glucose Study (phase 1). Soz Praventivmed. 2002;47(6):408-26. [PubMed: 12643001].
  • 5. Sarraf-Zadegan N, Boshtam M, Malekafzali H, Bashardoost N, Sayed-Tabatabaei FA, Rafiei M, et al. Secular trends in cardiovascular mortality in Iran, with special reference to Isfahan. Acta Cardiol. 1999;54(6):327-33. [PubMed: 10672288].
  • 6. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, et al. WHO study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). Bull World Health Organ. 2005;83(11):820-9. [PubMed: 16302038]. [PubMed Central: PMC2626468].
  • 7. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Prevalence of coronary heart disease among Tehran adults: Tehran Lipid and Glucose Study. East Mediterr Health J. 2009;15(1):157-66. [PubMed: 19469439].
  • 8. Unwin N, Alberti KG. Chronic non-communicable diseases. Ann Trop Med Parasitol. 2006;100(5-6):455-64. doi: 10.1179/136485906X97453. [PubMed: 16899148].
  • 9. Darnton-Hill I, Nishida C, James WP. A life course approach to diet, nutrition and the prevention of chronic diseases. Public Health Nutr. 2004;7(1A):101-21. [PubMed: 14972056].
  • 10. Nissinen A, Berrios X, Puska P. Community-based noncommunicable disease interventions: Lessons from developed countries for developing ones. Bull World Health Organ. 2001;79(10):963-70. [PubMed: 11693979]. [PubMed Central: PMC2566669].
  • 11. Mirmiran P, Esmaillzadeh A, Azizi F. Detection of cardiovascular risk factors by anthropometric measures in Tehranian adults: Receiver operating characteristic (ROC) curve analysis. Eur J Clin Nutr. 2004;58(8):1110-8. doi: 10.1038/sj.ejcn.1601936. [PubMed: 15280905].
  • 12. Mirmiran P, Mohammadi F, Baygi F, Kalantary N, Azizi F. [Assessment of dietary intake based on the food guide pyramid in a group of Tehranian adults]. Razi J Med Sci. 2003;9(32):767-78. Persian.
  • 13. Mirmiran P, Mohammadi F, Allahverdian S, Azizi F. Estimation of energy requirements for adults: Tehran Lipid and Glucose Study. Int J Vitam Nutr Res. 2003;73(3):193-200. doi: 10.1024/0300-9831.73.3.193. [PubMed: 12847996].
  • 14. Esmaillzadeh A, Mirmiran P, Azizi F. Whole-grain consumption and the metabolic syndrome: A favorable association in Tehranian adults. Eur J Clin Nutr. 2005;59(3):353-62. doi: 10.1038/sj.ejcn.1602080. [PubMed: 15536473].
  • 15. Azizi F, Ghanbarian A, Madjid M, Rahmani M. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999-2000. J Hum Hypertens. 2002;16(5):305-12. doi: 10.1038/sj.jhh.1001399. [PubMed: 12082490].
  • 16. Azizi F, Rashidi A, Ghanbarian A, Madjid M. Is systolic blood pressure sufficient for classification of blood pressure and determination of hypertension based on JNC-VI in an Iranian adult population? Tehran Lipid and Glucose Study (TLGS). J Hum Hypertens. 2003;17(4):287-91. doi: 10.1038/sj.jhh.1001539. [PubMed: 12692573].
  • 17. Ghanbarian A, Rashidi A, Madjid M, Azizi F. Blood pressure measures and electrocardiogram-defined myocardial infarction in an Iranian population: Tehran Lipid and Glucose Study. J Clin Hypertens (Greenwich). 2004;6(2):71-5. [PubMed: 14872144].
  • 18. Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, et al. Serum lipid levels in an Iranian adults population: Tehran Lipid and Glucose Study. Eur J Epidemiol. 2003;18(4):311-9. [PubMed: 12803371].
  • 19. Azizi F, Raiszadeh F, Salehi P, Rahmani M, Emami H, Ghanbarian A, et al. Determinants of serum HDL-C level in a Tehran urban population: The Tehran Lipid and Glucose Study. Nutr Metab Cardiovasc Dis. 2002;12(2):80-9. [PubMed: 12189907].
  • 20. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract. 2003;61(1):29-37. [PubMed: 12849921].
  • 21. Rafiei M, Boshtam M, Sarraf-Zadegan N. Lipid profiles in the Isfahan population: An Isfahan cardiovascular disease risk factor survey, 1994. East Mediterr Health J. 1999;5(4):766-77. [PubMed: 11338699].
  • 22. Sarraf-Zadegan N, Boshtam M, Mostafavi S, Rafiei M. Prevalence of hypertension and associated risk factors in Isfahan, Islamic Republic of Iran. East Mediterr Health J. 1999;5(5):992-1001. [PubMed: 10983540].
  • 23. Azizi F, Rahmani M, Madjid M, Allahverdian S, Ghanbili J, Ghanbarian A, et al. Serum lipid levels in an Iranian population of children and adolescents: Tehran Lipid and Glucose Study. Eur J Epidemiol. 2001;17(3):281-8. [PubMed: 11680549].
  • 24. Azizi F, Mirmiran P, Azadbakht L. Predictors of cardiovascular risk factors in Tehranian adolescents: Tehran lipid and glucose study. Int J Vitam Nutr Res. 2004;74(5):307-12. doi: 10.1024/0300-9831.74.5.307. [PubMed: 15628667].
  • 25. MacLean DR, Petrasovits A, Connelly PW, Joffres M, O'Connor B, Little JA. Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults. Canadian Heart Health Surveys Research Group. Can J Cardiol. 1999;15(4):434-44. [PubMed: 10322253].
  • 26. Centers for Disease C; Prevention. Prevalence of selected cardiovascular disease risk factors among American Indians and Alaska Natives--United States, 1997. MMWR Morb Mortal Wkly Rep. 2000;49(21):461-5. [PubMed: 10882292].
  • 27. Sempos CT, Bild DE, Manolio TA. Overview of the Jackson heart study: a study of cardiovascular diseases in African American men and women. Am J Med Sci. 1999;317(3):142-6. [PubMed: 10100686].
  • 28. Hutchinson RG, Watson RL, Davis CE, Barnes R, Brown S, Romm F, et al. Racial differences in risk factors for atherosclerosis. The ARIC study. Atherosclerosis risk in communities. Angiology. 1997;48(4):279-90. doi: 10.1177/000331979704800401. [PubMed: 9112876].
  • 29. Hayes KC. Saturated fats and blood lipids: New slant on an old story. Can J Cardiol. 1995;11 Suppl G:39G-46G. [PubMed: 7585292].
  • 30. O'Connor GT, Hennekens CH, Willett WC, Goldhaber SZ, Paffenbarger RS Jr, Breslow JL, et al. Physical exercise and reduced risk of nonfatal myocardial infarction. Am J Epidemiol. 1995;142(11):1147-56. [PubMed: 7485061].
  • 31. Rabbia F, Veglio F, Pinna G, Oliva S, Surgo V, Rolando B, et al. Cardiovascular risk factors in adolescence: Prevalence and familial aggregation. Prev Med. 1994;23(6):809-15. doi: 10.1006/pmed.1994.1138. [PubMed: 7855114].
  • 32. Andersen LB, Henckel P, Saltin B. Risk factors for cardiovascular disease in 16-19-year-old teenagers. J Intern Med. 1989;225(3):157-63. [PubMed: 2703797].
  • 33. Lauer RM, Connor WE, Leaverton PE, Reiter MA, Clarke WR. Coronary heart disease risk factors in school children: The Muscatine study. J Pediatr. 1975;86(5):697-706. [PubMed: 1133650].
  • 34. al-Nuaim AR, al-Rubeaan K, al-Mazrou Y, al-Attas O, al-Daghari N. Prevalence of hypercholesterolemia in Saudi Arabia, epidemiological study. Int J Cardiol. 1996;54(1):41-9. [PubMed: 8792184].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments